Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor

Andrès, Emmanuel; Kurtz, Jean Emmanuel; Milch, Catherine; Kaltenbach, Georges; Alt, M.; Weber, Jean Christophe; Sibilia, Jean; Schlienger, J. L.; Dufour, Patrick; Maloisel, Frédéric

doi:10.1016/s0002-9343(02)01064-1

Cited by 38 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it is speculated that the incidence of adverse effects may increase as the number of oral medicines used in combination increases. It is reported that G-CSF, a hematopoietic growth factor that shortens the duration of neutropenia, is useful for the treatment of agranulocytosis (9). The present patient attained complete hematologic recovery after the removal of the causative drugs.…”

Section: Discussionsupporting

confidence: 48%

“…Although we did not investigate antineutrophil antibodies, cibenzoline or dabigatran, or both could be offending drug(s) for the immune-mediated agranulocytosis of the present case. Drugs responsible for agranulocytosis are antibiotics, antithyroid drugs, antiplatelet agents, non-steroidal antiinflammatory drugs, and other drugs (9,10). In elderly patients with non-chemotherapy, drug-induced agranulocytosis presents commonly with severe infections, and thus results in a high mortality rate (11).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Agranulocytosis Immediately after Oral Administration of Cibenzoline and Dabigatran in a Patient with Paroxysmal Atrial Fibrillation

et al. 2012

View full text Add to dashboard Cite

This case report describes agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a 70-year-old woman with paroxysmal atrial fibrillation (AF). No blasts were found in peripheral blood and bone marrow, and the white blood cell count increased abruptly by intravenous administration of granulocyte colony-stimulation factor, suggesting an allergic response caused by cibenzoline or dabigatran, or both. Though antiarrhythmic drugs with anticoagulation therapy are commonly used to treat paroxysmal AF, caution has to be paid to drug-induced agranulocytosis.

show abstract

Section: Discussionsupporting

confidence: 48%

Section: Discussionmentioning

confidence: 99%

Agranulocytosis Immediately after Oral Administration of Cibenzoline and Dabigatran in a Patient with Paroxysmal Atrial Fibrillation

et al. 2012

View full text Add to dashboard Cite

show abstract

“…To our knowledge, no data is available with pegylated G-CSF. The most recent, major studies on haematopoietic growth factors use in drug-induced agranulocytosis are described in table 3 [18][19][20][21][22]. In our aforementioned cohort, a faster haematological non significantly recovery (neutrophil count > 1.5 x 109/L) was observed in the haematopoietic growth factors group: 2.1 days (p=0.057) [8].…”

Section: Usefulness Of Haematopoietic Growth Factormentioning

confidence: 73%

Diagnosis and Management of Idiopathic Drug-Induced Severe Neutropenia and Agranulocytosis

Andrès¹,

Mourot-Cottet²,

Maloisel³

2017

SOJPPS

Self Cite

View full text Add to dashboard Cite

“…The use of G-CSF shortens the mean time of grade 4 neutropenia after high-dose chemotherapy by about 2 days (6.6 ± 3.9 days versus 8.8 ± 4.9 days, P \ 0.04) [30]. G-CSF can also decrease the requirement for blood product support due to its positive effects on megakaryopoiesis and erythropoiesis [31].…”

Section: Nonementioning

confidence: 99%

Successful autologous peripheral blood stem cell transplantation in a Jehovah’s Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products

et al. 2008

View full text Add to dashboard Cite

We present a case report of a successful high-dose melphalan therapy and autologous stem cell transplantation without the use of allogeneic blood product support in a 70-year-old patient suffering from multiple myeloma. Based on the experience in this case and thorough evaluation of the literature, we consider pre-transplant Hb level of 11-12 g/dl, platelet count higher than 70/nl, good WHO performance status of two and lower and informed consent as important eligibility criteria. During cytopenia recommended supportive measures include growth factor support with erythropoietin and G-CSF, p.o. iron treatment as well as prophylactic use of anti-fibrinloytic agents. Furthermore we discuss additional options that might be considered depending on the individual factors as e.g. pre-transplant collection and cryoconservation of autologous platelet concentrates. Moreover, an analysis of socio-economic issues regarding this procedure is presented. We conclude that allogeneic blood product free transplantation is a feasible procedure that can be offered to the patients belonging to distinct religious groups refusing allogeneic blood products as Jehovás Witnesses and patients presenting other contraindications for transfusions.

show abstract

Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor

Cited by 38 publications

References 13 publications

Agranulocytosis Immediately after Oral Administration of Cibenzoline and Dabigatran in a Patient with Paroxysmal Atrial Fibrillation

Agranulocytosis Immediately after Oral Administration of Cibenzoline and Dabigatran in a Patient with Paroxysmal Atrial Fibrillation

Diagnosis and Management of Idiopathic Drug-Induced Severe Neutropenia and Agranulocytosis

Successful autologous peripheral blood stem cell transplantation in a Jehovah’s Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products

Contact Info

Product

Resources

About